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Abstract
Background: Cytokines of the transforming growth factor b (TGF-b) superfamily exert effects on proliferation,
apoptosis and differentiation in various cell types. Cancer cells frequently acquire resistance to the anti-proliferative
signals of TGF-b, which can be due to mutations in proteins of the signalling cascade. We compared the TGF-b-
related signalling properties in B-cell lymphoma cell lines that were sensitive or resistant to TGF-b-induced anti-
proliferative effects.
Results: TGF-b sensitive cell lines expressed higher cell surface levels of the activin receptor-like kinase 5 (Alk-5), a
TGF-b receptor type 1. The expression levels of the other TGF-b and bone morphogenetic protein receptors were
comparable in the different cell lines. TGF-b-induced phosphorylation of Smad2 was similar in TGF-b sensitive and
resistant cell lines. In contrast, activation of Smad1/5 was restricted to cells that were sensitive to growth inhibition
by TGF-b. Moreover, with activin A we detected limited anti-proliferative effects, strong phosphorylation of Smad2,
but no Smad1/5 phosphorylation. Up-regulation of the TGF-b target genes Id1 and Pai-1 was identified in the
TGF-b sensitive cell lines. Constitutive phosphorylation of MAPK p38 was restricted to the TGF-b sensitive cell lines.
Inhibition of p38 MAPK led to reduced sensitivity to TGF-b.
Conclusions: We suggest that phosphorylation of Smad1/5 is important for the anti-proliferative effects of TGF-b
in B-cell lymphoma. Alk-5 was highly expressed in the sensitive cell lines, and might be important for signalling
through Smad1/5. Our results indicate a role for p38 MAPK in the regulation of TGF-b-induced anti-proliferative
effects.
Background
T h em e m b e r so ft h eT G F - b superfamily of cytokines,
which consists of TGF-bs, bone morphogenetic proteins
(BMPs) and activins, exert potent effects on prolifera-
tion, apoptosis and differentiation on many different cell
types, including primary B cells [1,2]. The signalling is
initiated through heterotetrameric complexes of type I
and type II receptors. The cytokines bind to a type II
receptor, and type I is recruited and activated through
phosphorylation. There are five type II and seven type I
receptors which form complexes with the TGF-b super-
family of cytokines. TGF-b induces signalling through
TGF-b receptor type II (TbRII) and Alk-5 (type I),
whereas activin A and B induce signalling through acti-
vin receptor type II (ActRII), activin receptor type II b
(ActRIIb), Alk-4 and Alk-7 (type I) [3]. The intracellular
receptor regulated Smad proteins (R-Smads) are phos-
phorylated by the type I receptors. Smad2 and 3 are the
main R-Smads involved in TGF-b and activin signalling
[4]; although several recent reports have shown that
TGF-b can induce Smad1/5/8 signalling as well [5,6].
BMPs activate Smad1/5/8. R-Smads interact with the
common Smad, Smad4, and translocate to the nucleus,
where the complex, together with other transcription
factors, regulates gene expression of e.g. Pai-1. Pai-1
plays an important role throughout many cell systems,
and is involved in cell motility, angiogenesis and cancer
progression [7] in addition to anti-proliferative activity
[8]. It has been shown that inhibitory Smads,
Smad6 and 7, inhibit the pathway at several levels,
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between R-Smads and Smad4 [3]. There is extensive
crosstalk with other signalling pathways, such as p38,
E R K 1 / 2 ,J N K ,P I 3 Ka n dW n t[ 9 ] .I ti ss u g g e s t e dt h a t
this regulation often occurs through phosphorylation of
the linker region of R-Smads, which can be activating or
inhibitory to the effects of TGF-bs, activins or BMPs.
In cancer, TGF-b frequently loses its anti-prolifera-
tive effects, and sometimes gains pro-proliferative fea-
tures, often associated with epithelial-to-mesenchymal-
transition and metastasis of epithelial cells. Loss of
anti-proliferative effects can be due to mutations, gene
silencing or over-expression of inhibitors [10,11]. In
lymphoma and other haematological malignancies,
aberrant expression of receptors and mutations in
Smads have been found, although the reported fre-
quencies of aberrations involving the TGF-b pathway
in lymphoma are lower than in many other cancer
types [12,13]. For example, down-regulation of TbRII
RNA has been demonstrated in Burkitt lymphoma
(BL) cell lines which express the full range of latent
EBV genes [14].
Our aim was to elucidate the effects of TGF-b and
activin A on lymphoma cell lines, to study the signalling
pathways involved and to look for possible mechanisms
behind sensitivity or resistance to these cytokines. We
suggest that signalling through Smad1/5 can be impor-
tant for maintaining sensitivity to TGF-b growth inhibi-
tory effects. In addition, constitutively active p38 MAPK
indicates a role for this kinase in the regulation of TGF-
b-induced anti-proliferative effects.
Results
B-cell lymphoma show reduced sensitivity to TGF-b
compared to primary B cells
Many cancer types develop resistance to TGF-b-induced
growth inhibition. We tested the anti-proliferative effects
of TGF-b on 11 different B-cell lymphoma cell lines, and
compared these results to human peripheral blood CD19
+
B cells. For further studies on signalling we selected five of
these cell lines; three of these showed high sensitivity to
TGF-b treatment; although not to the same extent as pri-
mary B cells, whereas two were resistant to the growth
inhibiting effects of TGF-b (Figure 1A). In line with pre-
viously published data, TGF-b treatment of primary B
cells inhibited proliferation by 85% compared to non-trea-
ted control B cells (Figure 1A). More data on additional
cell lines are included in Additional file 1, Fig. S1 (two sen-
sitive cell lines, Oci-Ly 3 and Oci-Ly 10, and one resistant
cell line, Raji).
In addition to TGF-b, we tested the anti-proliferative
effects of activin A and B, and detected no major effects
on proliferation by these cytokines (Figure 1B and data
not shown). Primary B cells were partly inhibited by
activin A, with a mean inhibition of 34% (n =3 ,d a t a
not shown).
Additionally, we measured cell division to compare
the effects of TGF-b in sensitive and resistant cells. In
the resistant SUDHL-4 cells no inhibition of cell division
was detected. In contrast, TGF-b induced a clear inhibi-
tion in BL-41 cells after three days, as evidenced by the
CFSE histograms (Figure 1C).
TGF-b sensitive cell lines express high cell surface levels
of Alk-5
To determine the role of the different TGF-b receptors
during Smad signalling in B-cell lymphoma, we measured
endogenous cell surface levels of the receptors Alk-1,
Alk-5 and TbRII by flow cytometry on lymphoma cell
lines and primary B cells. The TGF-b sensitive cell lines
expressed higher levels of Alk-5 compared to the resis-
tant cell lines and primary B cells (Figure 2A and 2B).
The specificity of the anti-Alk-5 antibody was tested by
blocking with the peptide used for immunization before
Figure 1 B-cell lymphoma cell lines show reduced sensitivity to
growth inhibition by TGF-b. B-cell lymphoma cell lines and
primary B cells were treated with or without TGF-b (A) and B-cell
lymphoma cell lines were treated with or without activin A (B) and
[
3H]-thymidine incorporation was determined after 72 h. [
3H]-
thymidine was added for the last 4 or 16 h, for cell lines and
primary cells, respectively. Depicted is relative [
3H]-thymidine
incorporation in percentage, compared to controls of each cell type
(mean ± SEM, n = 6 (A), n = 3 - 4 (B)). Treated vs. control groups (A)
were subjected to Wilcoxon non-parametric test. TGF-b-treated cells
significantly different from the control group are indicated by
asterisk (*), p < 0.05. (C) SUDHL-4 and BL-41 cells were labelled with
5 μM CFSE for 10 min and grown for three days with and without
TGF-b. CFSE staining intensity was measured by flow cytometry. The
data is representative of three similar experiments.
Bakkebø et al. BMC Immunology 2010, 11:57
http://www.biomedcentral.com/1471-2172/11/57
Page 2 of 10flow cytometry (data not shown). TbRII was expressed in
all cell lines tested and in primary B cells, with no strik-
ing differences between TGF-b sensitive and resistant
cell lines (Figure 2A and 2B). Alk-1 was expressed at low
levels (Figure 2A). Furthermore, the type I and type II
activin receptors (Alk-4, Alk-7, ActRII and ActRIIb) were
similarly expressed in all cell lines (data not shown). It
has been shown that TGF-b can signal through the BMP-
receptors Alk-2 and Alk-3 [5]. We therefore examined
the expression levels of these two BMP type I receptors.
Of the sensitive cell lines, only ROS-50 expressed low
levels of Alk-2 and Alk-3, whereas Ramos expressed
some Alk-2 and higher levels of Alk-3 (Huse, K. et al.,
submitted).
Activation of Smad1/5 in TGF-b sensitive cells
To investigate signalling pathways triggered by TGF-b,
Western immunoblotting analysis was performed. TGF-
b induced activation of the canonical Smad2 pathway in
primary B cells (data not shown) and in all cell lines,
except K-422 (Figure 3A, Additional file 2, Fig. S2 and
Additional file 3, Fig. S3). However, we detected no
major differences in levels of Smad2 phosphorylation
between sensitive and resistant cell lines. Recently, there
Figure 2 Expression of cell surface TGF-b receptors. Endogenous levels of the receptors Alk-5, TbR I Ia n dA l k - 1w e r ed e t e r m i n e db yf l o w
cytometry. Illustrated is (A) median fluorescence intensity relative to irrelevant control for primary B cells and five cell lines (mean ± SEM, n =3 )
and (B) dot plot for BL-41 and SUDHL-4 (one representative of three). For Alk-1 and TbRII, biotinylated goat IgG is used as control, for Alk-5, goat
IgG is used as control.
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addition to Smad2/3 [5,6]. Interestingly, in the sensitive
c e l ll i n e sa sw e l la si np r i m a r yBc e l l s ,T G F - b induced
Smad1/5 phosphorylation (Figure 3A and 3B and
Additional file 2, Fig. S2). Immunoblotting with anti-
pSmad1/5/8 and anti-pSmad1/5 was comparable,
indicating that Smad8 is not important in TGF-b signal-
ling in B-cell lymphoma (data not shown). Activin A,
which had limited effects on proliferation, induced phos-
phorylation of Smad2 only in the TGF-b sensitive cell
lines. Phosphorylation of Smad1/5 was not detected
after activin A treatment (Figure 3C). We examined
endogenous levels of Smad1a n dS m a d 2p r o t e i n s ,a n d
found that Ramos and ROS-50 cells expressed higher
levels of Smad1 compared to the other cell lines. No
major differences in Smad2 levels were observed (Figure
3A). Taken together, the data suggest that Smad1/5 is
involved in controlling the anti-proliferative effects of
TGF-b in B-cell lymphoma cell lines.
To check whether inhibitory Smads play a role in
resistance to TGF-b, we assessed the endogenous pro-
tein levels of Smad6 and 7. However, only minor differ-
ences in expression levels were seen when comparing
the different cell lines (data not shown).
Activation of TGF-b target genes
To investigate whether the TGF-b-induced signalling
continued into the nucleus and up-regulated known
TGF-b target genes, we measured Pai-1 mRNA. Inter-
estingly, TGF-b induced up-regulation of Pai-1 in two of
the sensitive cell lines (Figure 4A). In addition, we
demonstrated that Id1, a known BMP target gene, was
induced to different degrees upon TGF-b treatment in
the sensitive cell lines (Figure 4B). The resistant cell
lines showed no up-regulation of either of these target
genes (Figure 4A and 4B). These data imply that there
are differences between TGF-b sensitive and resistant
cell lines regarding induction of TGF-b target genes.
p38 MAPK is constitutive active in TGF-b sensitive cells
We further investigated other signalling pathways
known to crosstalk with the canonical Smad pathway.
Of interest, we found high constitutive levels of phos-
phorylated p38 MAPK (Thr180/Tyr182) in the TGF-b
sensitive cell lines (Figure 5A and Additional file 4, Fig.
S4). The resistant cell lines expressed minimal levels of
active p38 MAPK compared to the sensitive cell lines.
We also found high constitutive levels of phosphorylated
ERK1/2 MAPK (Thr202/Tyr204) in the TGF-b resistant
cell lines, but also in one of the sensitive cell lines
(Figure 5A). TGF-b did not affect the level of phos-
phorylated ERK1/2. Screening of other activated signal-
ling molecules, i.e. phosphorylated Akt, JNK MAPK,
TAK and MKK 3/6 did not reveal any correlation to
sensitivity or resistance to TGF-b (data not shown).
Due to high levels of activated ERK1/2 MAPK in the
resistant cell lines, and the fact that this can alter the
canonical Smad signalling pathway through phosphoryla-
tion of the linker region, we investigated phosphorylation
Figure 3 TGF-b sensitive cell lines signal through Smad1/5 in
addition to Smad2. Cell lines were stimulated with or without
TGF-b (A) and with activin A or TGF-b (C) for 1 h, and primary B
cells were stimulated with or without TGF-b for 30 min, 1, 2, 4, 6
and 24 h (B), lysed, and subjected to western immunoblotting
analysis, with the indicated primary antibodies. Staining with an
anti-phospho-Smad1/5 antibody was applied to confirm that Smad8
was not involved (data not shown). The positive control (Ctr) in
Fig. 3B is BL-41 total cell lysate. Presented is one representative blot
out of three with one representative actin loading control.
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(Ser206) linker regions. Smad1 linker phosphorylation
was detectable in two TGF-b sensitive cell lines, and
TGF-b only slightly altered the level of linker phosphory-
lation in these cell lines (Figure 5B). In contrast, no
major differences in Smad2 linker region phosphorylation
were observed between the sensitive and resistant cell
lines. These results imply that activated ERK1/2 MAPK
c o u l db ei n v o l v e di nr e s i s t a n c et oT G F - b in B-cell lym-
phoma cell lines, although phosphorylation of the linker
region of Smad2 seems not to be the mechanism. We
suggest that activated p38 MAPK could be important for
sensitivity to TGF-b.
Inhibition of p38 MAPK leads to reduced sensitivity
to TGF-b
To test whether p38 contributes to TGF-b sensitivity,
we used the p38-specific inhibitor SB203580 in the
TGF-b sensitive cell line Ramos. When phosphorylation
of p38 was inhibited, we observed reduced sensitivity to
TGF-b-induced anti-proliferative effects compared to
the control group (Figure 6). TGF-b induced cell death
in 39% of the cells, whereas TGF-b together with
SB203580 differed significantly with 29% cell death (p <
0.05, Figure 6). The p38 inhibitor also reduced TGF-b-
induced apoptosis as determined by TUNEL analysis
(data not shown). Inhibition of ERK1/2 MAPK did not
Figure 4 Pai-1 and Id1 are up-regulated upon TGF-b treatment. (A) Cell lines were stimulated with or without TGF-b for 1, 6 or 24 h, before
total RNA was isolated, cDNA was synthesized and real-time RT-PCR was conducted with Pai-1 as target gene. Illustrated is relative Pai-1 mRNA
expression (one representative experiment of three, ± SD). (B) Cells were stimulated without or with TGF-b for 3 h, lysed, and subjected to
western immunoblotting analysis, with anti-Id1 Ab, and anti-actin Ab as loading control. Shown is one representative blot out of three.
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(data not shown). Thus, inhibition of p38 MAPK par-
tially counteracts TGF-b-induced growth suppression in
Ramos cells, suggesting a role for p38 MAPK in the reg-
ulation of TGF-b-induced anti-proliferative effects.
Discussion
It is known from several cancer types that TGF-b loses
its anti-proliferative effects, often due to mutations in
receptors or Smad proteins [15,16]. Haematological
malignancies, especially B-cell lymphoma, have received
less attention regarding TGF-b signalling. We sought to
elucidate the effects of TGF-b on cell lines from differ-
ent B-cell lymphoma subtypes, working with endogen-
ous levels of gene expression. We found that the B-cell
lymphoma cell lines examined displayed reduced sensi-
tivity to TGF-b compared to primary B cells. This indi-
cates that loss of sensitivity towards the growth
inhibitory effects of TGF-b can be of importance for the
development of B-cell lymphoma.
Although Smad2 and 3 are the main R-Smads for
TGF-b signalling, we found no clear differences in TGF-
b-induced Smad2 signalling when comparing sensitive
and resistant cell lines. Moreover, we detected that acti-
vin A and B exerted limited anti-proliferative effects on
the B-cell lymphoma cell lines, even though clear
Smad2 signalling was observed in the TGF-b-sensitive
cell lines upon activin A stimulation. This further indi-
cates that Smad2 phosphorylation is not directly corre-
lated to inhibition of proliferation. Of note, recent
studies have revealed that TGF-b can also activate the
Smad1/5/8 pathway. Interestingly, we observed a clear
correlation between sensitivity to TGF-b and Smad1/5
phosphorylation as TGF-b induced phosphorylation of
Smad1/5 in sensitive cell lines only. Smad1/5 signalling
upon TGF-b treatment has to our knowledge previously
not been reported in primary B cells. These data suggest
that signalling through Smad1/5 is important for the
functional effects of TGF-b on B-cell lymphoma cell
lines of different origin. In agreement with our data,
Munoz et al. have previously reported induction of
Smad1 phosphorylation upon TGF-b treatment in folli-
cular lymphoma cell lines and one diffuse large B-cell
lymphoma cell line [17]. Moreover, they demonstrated
that the functional effects of TGF-b were diminished
upon treatment with Smad1 siRNA. Taken together,
available data suggest that Smad1/5 is crucial for the
anti-proliferative effects of TGF-b.
We found that sensitive cell lines showed higher
endogenous Alk-5 levels and this expression correlated
to Smad1/5 activation, as it was highly expressed in the
cell lines where TGF-b induced phosphorylation of
Figure 6 Inhibition of p38 MAPK leads to less TGF-b-induced
cell death. Ramos cells were treated with or without the p38 MAPK
specific inhibitor SB203580 for 1 h, followed by incubation with or
without TGF-b, stained with PI after 72 h and analyzed by flow
cytometry. Presented is percentage of PI-positive cells (mean ± SEM,
n = 6). Treatment with p38 MAPK inhibitor and TGF-b together
were subjected to Wilcoxon non-parametric test against treatment
with TGF-b alone. Significance is indicated with asterisk (*), p < 0.05.
Figure 5 Expression of phosphorylated ERK1/2 and p38 MAPK.
Cells were stimulated with or without TGF-b for 1 h (A) or 30 min
(B), lysed, and subjected to western immunoblotting analysis with
the indicated primary antibodies. Shown is one representative blot
out of three.
Bakkebø et al. BMC Immunology 2010, 11:57
http://www.biomedcentral.com/1471-2172/11/57
Page 6 of 10Smad1/5. Similar results have been found in other cell
systems [6]. Data by Wrighton et al.s u g g e s tt h a tA l k - 5
has the ability to phosphorylate Smad1, and that Smad1
can co-precipitate Alk-5 in HEK293T cells. In other cell
systems, additional receptors have been demonstrated to
be necessary. Daly et al.p r o v e dt h a tT bRII and Alk-5
were required, but not sufficient for Smad1/5 phosphor-
ylation [5]. They found that Alk-2 or Alk-3 can co-
precipitate with TbRII and Alk-5, and that forming of
the receptor complexes is dependent on cell type.
Among the cell lines which induced Smad1/5 signalling,
only Ramos expressed some Alk-2 and higher levels of
Alk-3. Alk-1 was expressed at such low levels that it is
unlikely to be involved. This was expected, because Alk-
1 is believed to be present only in endothelial cells
[18,19]. TbRII is most likely involved in Smad2 and
Smad1/5 signalling in our cell lines, as it is the only
known type II receptor for TGF-b [3]. However, the
TbRII expression level differed in both sensitive and
resistant cell lines. Smad2 signalling upon activin A sti-
mulation is detected in Ramos, ROS-50 and BL-41 cells.
Abrogated Smad2 signalling in the other cell lines is
most likely not due to reduced expression of receptors,
as we detected nearly equal expression of all known
activin receptors in our cell lines. Thus, Alk-5 might be
the receptor which is crucial for Smad1/5 signalling and
TGF-b-induced anti-proliferative effects.
Previous work has shown a correlation between acti-
vated p38 MAPK and the apoptotic effects of TGF-b in
BL-41 cells [20]. In accordance with this study, we
found that p38 was constitutively phosphorylated in cell
lines sensitive to growth inhibition by TGF-b.I nc o n -
trast, TGF-b resistant cell lines expressed high levels of
phosphorylated ERK1/2 MAPK. We successfully inhib-
i t e dp 3 8i nR a m o sc e l l s ,a n ds h o w e dt h a tt h ea n t i -
apoptotic effects of TGF-b is dependent, at least to
s o m ed e g r e e ,o nt h ea c t i v i t yo fp 3 8 .I ti sp o s s i b l et h a t
p38-induced sumoylation of Smad4, which enhances
TGF-b and BMP target gene activation, could explain
the positive effect of phosphorylated p38 on TGF-b
growth inhibition, as suggested by Ohshima et al.[ 2 1 ] .
Possibly, one needs to induce ERK1/2 in addition to
inhibiting p38 to diminish the effects of TGF-b.I n t e r -
estingly, we detected phosphorylated ERK1/2 in Ramos
cells, whereas in BL-41 and ROS-50 cells this phosphor-
ylation was not seen. This might explain why the effects
of TGF-b were reduced only in Ramos cells and not in
BL-41 and ROS-50 cells (data not shown) upon adding
the p38 inhibitor. Phosphorylation of the R-Smad linker
region may inhibit translocation of activated Smad-com-
plexes to the nucleus. It is demonstrated that ERK1/2
phosphorylates the linker region of Smad1 and Smad2,
and this can inhibit signal transduction and the anti-
proliferative effects of TGF-b [22,23]. However, the
consequences of linker-phosphorylation remain contro-
versial [24], and we did not detect any higher levels of
phosphorylation of the Smad2 linker region in TGF-b
resistant compared to sensitive cell lines. The Smad1
linker region was phosphorylated in Ramos and ROS-50
cells, and this might even induce Smad1/5 signalling by
TGF-b in these cells.
Id1 is a known BMP-responsive gene, which is up-
regulated upon Smad1/5/8 signalling [25,26]. However,
TGF-b-induction of Id proteins has previously been
found in a BL cell line, CA46 [27], although it was not
investigated whether Smad1/5 signalling was involved.
We demonstrate induction of Id1 protein in the TGF-b
sensitive cell lines (BL-41, Ramos and ROS-50) after 3 h
of TGF-b stimulation. Opposed to that, Daly et al. did
not detect induction of a luciferase reporter containing
two repeats of a BMP response element in cell types
where TGF-b also signals through Smad1/5 [5]. Induc-
tion of Id1 is possibly dependent on the cell type. It has
been reported that TGF-b represses Id expression in
epithelial cells [28].
Conclusion
To summarize, three B-cell lymphoma cell lines showed
sensitivity to the TGF-b anti-proliferative effects. Sensi-
tivity to growth inhibition by TGF-b m i g h td e p e n do n
Smad1/5 signalling in lymphoma cell lines, which possi-
bly initiates via Alk-5 and terminates in up-regulation of
Id1 and other target genes. We suggest that the regula-
tion of proliferation by TGF-b is at least partly depen-
dent on activated p38 MAPK. Further knock-down
studies need to be assessed to confirm this theory. In
the future, therapies which can restore sensitivity of
lymphoma cells to TGF-b growth control by inducing
Smad1/5 signalling can be helpful in treatment of B-cell
lymphoma patients.
Methods
Cell culture
BL cell lines Ramos, BL-41 and Raji, diffuse large B-cell
lymphoma cell lines of germinal centre B type SUDHL-
4 and of activated B cell type Oci-Ly 3 and Oci-Ly 10
and follicular lymphoma cell lines K-422 and ROS-50
were cultured in RPMI (PAA Laboratories, Austria) with
100 Units/ml penicillin and 0.1 mg/ml streptomycin
(PAA Laboratories) and 10% fetal calf serum (PAA
Laboratories), except for the Oci Ly-cells, which were
cultured in IMDM (Invitrogen, CA, USA) with 55 μM
b-Mercaptoethanol (Invitrogen), 100 Units/ml penicillin
and 0,1 mg/ml streptomycin (PAA Laboratories) and
10% human plasma (SeraCare Life Sciences, Inc.,
California, USA), at 37°C with 5% CO2 in air. Prior to
all experiments, cells were grown under serum free con-
ditions over night in X-VIVO 15 (BioWhittaker,
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blood were isolated using CD19
+ Dynabeads (Invitro-
gen), as described by Rasmussen et al. [29]. Peripheral
blood was provided by the Blood Bank at Ullevål Uni-
versity Hospital with formal agreement by the blood
donors, and approval by the regional ethics committee.
Reagents
Carrier-free huTGF-b1 (10 ng/ml) and activin A and B
(10 ng/ml) were purchased from R&D Systems (MN,
USA). Anti-IgM (10 μg / m l )w a so b t a i n e df r o mJ a c k s o n
Immuno Research (PA, USA). [
3H]-thymidine was pur-
chased from American Radiolabeled Chemicals (MO,
USA). The following Ab were used: Anti-phospho-
Smad2, -phospho-Smad1/5/8, -phospho-Smad1/5,
-Smad1, -Smad2, -Smad6, -phospho-p38 MAPK, -p38
MAPK, -phospho-ERK1/2 MAPK -phospho-TAK 1,
-phospho-MKK3/MKK6 and -phospho-JNK MAPK Ab
(Cell Signalling Technology, MA, USA), anti-actin, -ERK
MAPK and -Id1 Ab (Santa Cruz, CA, USA), anti-Smad7
Ab (Abcam, MA, USA), biotinylated anti-Alk-1, -TbRII,
-ActRII and -ActRIIb Ab and anti-Alk-4 and -Alk-5 Ab
(R&D systems), anti-Alk-7 Ab (Millipore, MA, USA)
and HRP-coupled secondary anti-rabbit, -mouse and
-goat IgG Ab (DakoCytomation, Denmark). ERK inhibi-
tors FR180204 and UO126 and p38 inhibitor SB203580
w e r ep u r c h a s e df r o mC a l b i o c h e m( D a r m s t a d t ,
Germany). The Alk-5 peptide used for blocking of anti-
Alk-5 antibody was obtained from R&D systems.
Cell proliferation assays
Cells were harvested after 72 h using an automated cell
harvester (Filtermate 196, Packard Instrument Company
I n c . ,C T ,U S A ) ,a n d[
3H]-thymidine incorporation into
DNA was measured on a scintillation counter (Top-
Count, Packard Instrument Company Inc.). Assays were
performed in triplicates in round bottom 96-well plates,
200 μl per well; 0.1 × 10
6 cells/ml for cell lines and
0.375 × 10
6 cells/ml for B cells. [
3H]-thymidine was
added 4 or 16 h before measurement, respectively.
To monitor cell death, 5 μg/ml PI was used for analy-
sis by flow cytometry (Becton Dickinson, FACSCalibur,
NJ, USA). Cell death was measured for every functional
experiment conducted.
For CFSE proliferation analysis cells were labeled with
5 μM CFSE (Molecular Probes, OR, USA) in PBS with
0.1% BSA for 10 min at 37°C. The labeling reaction was
quenched by addition of cold PBS with 20% FCS. Cells
were incubated in pre-warmed X-VIVO 15 and cultured
over night before cells with identical CFSE staining
intensity was sorted. The CFSE sorted cells were cul-
tured for up to 3 days with or without TGF-b.F A C S
analysis allowed gating on individual CFSE generations
(Becton Dickinson, FACS CantoII).
Apoptosis assay
Cells were harvested after 3 days and stained with TUNEL
(Roche, Switzerland) according to the manufacture’s pro-
tocol. Cells were analyzed by flow cytometry (Becton Dick-
inson, FACSCalibur).
Western immunoblotting analysis
Cells were lysed in Tris lysis buffer, pH 6.8 (62.7 mM
Tris-HCl, 10% (v/v) glycerol, 2.3% (w/v) SDS, 5% b-Mer-
captoethanol, 1× protease inhibitor mixture (Complete
Mini, Roche) and 1× phosphatase inhibitor mixture
(PhosSTOP, Roche)). Lysates were incubated at 95°C for
10 min, cleared by centrifugation at 15700 g for 5 min
and protein concentrations were determined with the
BioRad (CA, USA) protein assay. Samples (30-40 μg/
lane) were run on 10% or 12% SDS-polyacrylamide gels
(Pierce, IL, USA) or 10% Tris-HCl Criterion gels
(BioRad) and transferred to PVDF membranes (Milli-
pore). Membranes were blocked in 5% non-fat dry milk
or 5% BSA (Sigma-Aldrich, MO, USA) in TBST buffer
pH 7.6, according to the antibody manufacturer’s proto-
col. PVDF membranes were incubated over night at 4°C
with antibody diluted in 5% non-fat dry milk or 5% BSA
in TBST buffer. HRP-conjugated anti-mouse, -goat and
-rabbit IgG antibodies incubated for 60 min at room
temperature were used followed by detection using ECL
or ECL-plus (GE Healthcare, NJ, USA).
Detection of cell surface receptor expression
Cells were blocked in 1 mg/ml g-globulin (aggregated at
63°C, 20 min (Sigma-Aldrich)) for 10 min on ice, prior
to staining with anti-Alk-1, -Alk-5 or -TbRII antibodies
for 30 min at 4°C. Avidin-PE (BioRad) was used as sec-
ond layer. Goat Ig and biotinylated Goat Ig were used
as controls. Cells were washed in PBS. Receptor levels
were detected by flow cytometry (Becton Dickinson,
FACSCalibur and FACS CantoII).
Real time RT-PCR analysis
RNA was isolated using the Absolutely RNA Miniprep
kit (Stratagene, CA, USA) following the manufacturer’s
instructions. RNA concentration was obtained using
NanoDrop-1000 Spectrophotometer (Thermo Fisher
Scientific Inc., MA, USA), and quality was assessed by
gel electrophoresis using 1.5% agarose gel. RNA was
stored at -80°C. Using the TaqMan kit (Applied Biosys-
tems, CA, USA), cDNA was obtained from 1 μgR N A
for each sample and 400 ng RNA for the minus reverse
transcriptase (-RT) negative controls. Conditions: 10
min at 25°C, 40 min at 42°C and 10 min at 95°C.
Real-time RT-PCR was conducted with TaqMan Uni-
versal PCR master mix (Applied Biosystems) with Pai-1
(Applied Biosystems) as the target gene and PGK-1
(Applied Biosystems) as the control gene. The cDNA
Bakkebø et al. BMC Immunology 2010, 11:57
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samples had a total volume of 25 μl, and were run on
ABI Prism 7000 Sequence Detection System. Conditions:
2 min at 50°C, 10 min at 95°C and 40 cycles of 15 s at
95°C and 1 min at 60°C. Relative expression levels were
calculated using the threshold cycle ΔΔCt-method as
described by the manufacturers’ protocol. Instead of
calibrating the samples to a control sample, samples
were calibrated to the number 10.
Statistical analysis
Wilcoxon non-parametric test was used for all statistical
measurements, with p-value less than 0.05 considered as
significant. The statistical significance analysis in Figure
1A has been conducted on primary data, although the
data depicted in the figure are normalized.
Additional material
Additional file 1: Fig. S1. B-cell lymphoma cell lines show reduced
sensitivity to growth inhibition by TGF-b. B-cell lymphoma cell lines
were treated with or without TGF-b and [
3H]-thymidine incorporation
was determined after 72 h. [
3H]-thymidine was added for the last 4 h.
Depicted is relative [
3H]-thymidine incorporation in percentage,
compared to controls of each cell type (mean ± SEM, n = 6).
Additional file 2: Fig. S2. TGF-b sensitive cell lines signal through
Smad1/5 in addition to Smad2. Cell lines were stimulated with or
without TGF-b for 1 h, lysed, and subjected to western immunoblotting
analysis, with the indicated primary antibodies. Presented is one
representative blot out of three. Actin was used as loading control.
Additional file 3: Fig. S3. Both TGF-b sensitive and resistant cell
lines signal through Smad2. The volume of each band from Western
immunoblots with pSmad2 and actin antibodies was calculated using
Quantity One Analysis Software to quantify the phosphorylation of
Smad2 upon TGF-b stimulation. The measured values were normalized
against actin and the relative expression in TGF-b-treated BL-41 cells.
Shown is relative pSmad2 expression in both sensitive and resistant cell
lines, n = 6 (mean ± SEM).
Additional file 4: Fig. S4. Sensitive cell lines express activated
p-p38. Cells were stimulated with or without TGF-b for 1 h, lysed and
subjected to western immunoblotting analysis with p-p38 and actin as
primary antibodies. Shown is one representative blot out of three, and
one representative actin control.
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